Wetzler M, Baer M R, Stewart S J, Donohue K, Ford L, Stewart C C, Repasky E A, Ferrone S
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Leukemia. 2001 Jan;15(1):128-33. doi: 10.1038/sj.leu.2401982.
Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based immunotherapies. The potential for applying T cell-based immunotherapy in the treatment of acute myeloid leukemia (AML) has stimulated interest in analyzing HLA class I antigen expression on leukemic blasts in this disease. Little information is available in the literature. We have analyzed HLA class I antigen expression on bone marrow samples from 25 newly diagnosed AML patients by indirect immunofluorescence staining with monoclonal antibodies. Five of these patients were also studied at relapse. Leukemic blasts were resolved from normal lymphocytes by staining with antiCD45 antibody; CD45 expression is dim on leukemia cells, but bright on lymphocytes. HLA class I antigen expression was higher on leukemic blasts than on autologous lymphocytes in all but one case. Moreover, there was no significant change in HLA class I antigen expression at relapse. These results suggest that abnormalities in HLA class I antigens are infrequent in AML and should not represent a major obstacle to the application of T cell-based immunotherapies in this disease.
人类白细胞抗原（HLA）I类分子限制细胞毒性T细胞与靶细胞之间的相互作用。HLA I类抗原表达和/或功能异常可能为肿瘤细胞提供逃避免疫监视和抵抗基于T细胞的免疫疗法的机制。在急性髓系白血病（AML）治疗中应用基于T细胞的免疫疗法的潜力激发了人们对分析该疾病白血病原始细胞上HLA I类抗原表达的兴趣。文献中相关信息较少。我们通过用单克隆抗体进行间接免疫荧光染色，分析了25例新诊断AML患者骨髓样本中HLA I类抗原的表达。其中5例患者在复发时也进行了研究。通过用抗CD45抗体染色将白血病原始细胞与正常淋巴细胞区分开；CD45在白血病细胞上表达较弱，但在淋巴细胞上表达较强。除1例病例外，所有病例中白血病原始细胞上的HLA I类抗原表达均高于自体淋巴细胞。此外，复发时HLA I类抗原表达无显著变化。这些结果表明，HLA I类抗原异常在AML中并不常见，不应成为在该疾病中应用基于T细胞的免疫疗法的主要障碍。
